ClinicalTrials.gg
CompletedNCT00037531Updated Aug 18, 2009

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

A Phase 3 interventional study of Sirolimus (RAPAMUNE) in Graft vs Host Disease and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-08-18.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies testing sirolimus in Graft vs Host Disease — 2 open to participants now, 5 under way, none of them phase 3. Sirolimus · Graft vs Host Disease.

Enrollment
Largest of 34
769 · median 34
Phase 3
6 of 35
none open now
Registered
2nd of 35
by date
Lead sponsor
5 of 35
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 35 studies testing sirolimus in Graft vs Host Disease, this one has the largest enrollment of the 34 interventional ones that give a count, is one of 6 in phase 3, and was the 2nd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

2 of the 35 studies testing sirolimus in Graft vs Host Disease are open now. Recruiting first, the newest first:

All 2 open studies →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing sirolimus in Graft vs Host Disease, or all of them as a file.
02

Study summary

To evaluate the safety of long-term administration of sirolimus oral solution for up to 5 additional years, or until the tablet formulation is commercially available (whichever occurs first) in solid organ transplant recipients who are currently receiving sirolimus and who have completed clinical trials with sirolimus (with or without cyclosporine (CsA). To evaluate the pharmacokinetics and safety of long-term administration of sirolimus tablets administered for up to 5 years, or until the tablet formulation is commercially available in solid organ transplant recipients who are currently receiving sirolimus and who have completed clinical trials with sirolimus (with or without CsA) or who are currently enrolled in protocol 0468E1-306-US.

03

Conditions studied

  • Graft vs Host Disease
  • Kidney Transplantation

Browse trials for

Keywords

  • Transplant
  • Kidney
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of sirolimus/blinded therapy in solid organ clinical trials (with or without CsA) with satisfactory compliance and an adequate safety profile.
  • Women of who have a negative pregnancy test before enrollment into this study and who agree to practice either a hormonal or barrier method of throughout the treatment period and for 3 months following discontinuation of sirolimus may be enrolled into the study.
  • Signed and dated

Exclusion criteria

Exclusion Criteria:

  • Unstable disease states, which in the opinion of the investigator would present a risk to the patient.
  • Known to macrolide antibiotics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Enrollment
769 participants (actual)

Interventions

06

Study locations

20 sites
  • Los Angeles, California 90057, United States
  • Los Angeles, California 90095-1752, United States
  • San Diego, California 92123, United States
  • Stanford, California 94304, United States
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia 30322, United States
  • Augusta, Georgia 30912, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202-5250, United States
  • New York, New York 10029, United States
  • Charlotte, North Carolina 28232, United States
  • Philadelphia, Pennsylvania 19141, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Charleston, South Carolina 29425-0777, United States
  • Edmonton, Alberta T6G 2B7, Canada
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Toronto, Ontario M5B 1W8, Canada
  • Toronto, Ontario M5G 2C4, Canada
  • Montreal, Quebec H2L 2W5, Canada
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00037531
First posted
May 20, 2002
Primary completion
Aug 2004
Completion
Aug 2004
Last update
Aug 18, 2009

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion